| Therapeutic | Bezetabart |
| Target | CD74/HLA class II histocompatibility antigen gamma chain |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFNFSDYGMHWVRQAPGKGLEWVAVIWYDGSISYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGTVEHGAVYGTDVWGQGTTVTVSS |
| Light Chain | DIQMTQSPSSVSASVGDRVTITCRASQGIGSWLAWYQQKPGKAPKLLIYAADRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHTYPLTFGGGTKVEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb ADC |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Phase-I/II |
| Estimated Status (Feb '25) | Discontinued |
| Recorded Developmental Technology | Modified at two specific positions with reactive 4-(azidomethyl)-L-phenylalanine residues |
| INN Year Proposed | 2023 |
| INN Year Recommended | 2024 |
| Companies Involved | Sutro Biopharma, BioNova Pharmaceuticals, Sutro Biopharma |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Non-Hodgkin's lymphoma, Acute myeloid leukaemia, Haematological malignancies, Multiple myeloma, Leukaemia |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
